Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
19.03
+0.84 (4.62%)
At close: Jan 17, 2025, 4:00 PM
19.29
+0.26 (1.37%)
After-hours: Jan 17, 2025, 7:45 PM EST
Summit Therapeutics Employees
Summit Therapeutics had 105 employees as of December 31, 2023. The number of employees increased by 28 or 36.36% compared to the previous year.
Employees
105
Change (1Y)
28
Growth (1Y)
36.36%
Revenue / Employee
n/a
Profits / Employee
-$1,873,133
Market Cap
14.03B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 105 | 28 | 36.36% |
Dec 31, 2022 | 77 | -33 | -30.00% |
Dec 31, 2021 | 110 | 29 | 35.80% |
Dec 31, 2020 | 81 | 11 | 15.71% |
Dec 31, 2019 | 70 | 9 | 14.75% |
Dec 31, 2018 | 61 | -15 | -19.74% |
Dec 31, 2017 | 76 | 36 | 90.00% |
Dec 31, 2016 | 40 | 3 | 8.11% |
Dec 31, 2015 | 37 | 14 | 60.87% |
Dec 31, 2014 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
SMMT News
- 2 days ago - Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade) - Seeking Alpha
- 4 days ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 days ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 13 days ago - Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 17 days ago - Best-Performing Stocks Of 2024 - Seeking Alpha
- 7 weeks ago - Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial - Seeking Alpha
- 7 weeks ago - Summit Therapeutics to Present at Upcoming Investor Conferences - Business Wire
- 2 months ago - Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo - Benzinga